Dehydroxymethylepoxyquinomicin (DHMEQ), an inhibitor of NFκB, induces apoptosis, increases the response to platinum-based drugs and reverses immunosuppression in ovarian cancer cells [102, 103]. This evidence concerns the gene NFKB1 and ovarian carcinoma.